HeartCare is a combined, single blood-draw test — pairing AlloMap (a gene-expression test) and AlloSure (a donor-derived cell-free DNA test) — used at some transplant centers as a non-invasive way to monitor for rejection, which can reduce how often you need an invasive surveillance endomyocardial biopsy once you're far enough out from transplant that your rejection risk has settled somewhat. It doesn't replace biopsies for everyone or at every point after transplant — think of it as another tool your team may use alongside biopsies, not automatically instead of them. (See Monitoring, Procedures & Labs After Transplant for how this fits into your overall surveillance schedule, and Life After Transplant for the full picture of ongoing post-transplant care.)
What Each Test Actually Measures
- AlloMap measures the activity level of a specific panel of genes in your white blood cells — genes whose expression pattern shifts in a recognizable way during active cellular rejection. The result is reported as a score from 0 to 40: a lower score is reassuring, while a higher score raises concern for rejection.
- AlloSure measures the percentage of donor-derived cell-free DNA (dd-cfDNA) circulating in your blood — tiny fragments of DNA that leak out when cells anywhere in your transplanted heart are damaged. Because that damaged-cell DNA specifically comes from the donor heart (genetically distinct from your own DNA), it can be measured separately from your own background cell-free DNA. A higher percentage suggests more donor-organ cell turnover/damage and raises concern for rejection; a very low percentage is reassuring.
Basis of Interpretation
(General reference points only — your transplant program's specific protocol and your own results always take precedence over any general number.)
- An AlloMap score below roughly 30 in the first 6 months after transplant, or below roughly 34 after 6 months, is generally considered reassuring for the absence of significant cellular rejection.
- An AlloSure result below roughly 0.15% is generally reassuring — this threshold has a strong negative predictive value, meaning a result this low makes clinically significant rejection quite unlikely.
- Higher or discordant results — either test above its threshold, or one reassuring while the other isn't — typically prompt your team to get a confirmatory endomyocardial biopsy rather than adjusting your immunosuppression on the blood test result alone. A notably elevated AlloSure with a reassuring AlloMap is a specific pattern worth your team looking closely at antibody-mediated rejection, since the two tests aren't equally sensitive to every rejection type.
Basis of Treatment
A reassuring HeartCare result may let your transplant team safely extend the interval before your next scheduled surveillance biopsy, or occasionally substitute for one during a lower-risk period of your follow-up. A concerning result prompts closer follow-up and typically a confirmatory biopsy — if rejection is confirmed, it's treated the same way biopsy-diagnosed rejection is treated regardless of how it was first flagged: an adjustment to your immunosuppression regimen tailored to how significant the rejection is. (See Complications After Transplant for how rejection itself is managed.)
Why Your Team Might Still Want Biopsies
These blood tests are typically not started until roughly 2 months after transplant, since rejection risk and the tests' reliability both behave differently in the earliest post-transplant period — direct tissue biopsy remains the standard in that window. Certain clinical situations (a prior rejection episode, specific risk factors, or genuinely unclear blood results) may also lead your team to keep biopsies in your surveillance plan even later on. Ask your own transplant team specifically how HeartCare fits into your monitoring schedule, since this varies by center and by your individual risk profile.
Common Questions
Does a good HeartCare result mean I definitely don't have rejection?
It substantially lowers the likelihood, particularly a low AlloSure result, but it's not an absolute guarantee — your team weighs it alongside your symptoms, exam, and overall clinical picture.
Will this replace all of my biopsies?
Not necessarily, and not for everyone — some patients continue a mix of both throughout their care; ask your team what your specific plan looks like.
Why do I need two different tests instead of just one?
Because they detect somewhat different things — AlloMap reflects cellular immune activity, while AlloSure reflects actual tissue damage to the donor heart — using both together gives a fuller picture than either alone.
Is this test the same as a biopsy?
No — it's a blood draw, not a procedure, which is exactly why it's valued as a less invasive option when it's appropriate for your situation.